

21st February, 2026

(1) BSE Limited
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

Scrip Code: 500087

(2) National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Dear Sir/Madam,

Sub: Update on US Food and Drug Administration (USFDA) inspection on Pharmathen International S.A.

In continuation with our intimation dated 7th and 14th January, 2026, the Company has been informed that USFDA has classified the current Good Manufacturing Practices ('cGMP') inspection at the Rodopi, Greece manufacturing facility of Pharmathen International S.A., the supply partner for Lanreotide Injection to Cipla USA Inc., a wholly owned subsidiary as Official Action Indicated ("OAI").

Please take the above information on record.

Yours faithfully,
For Cipla Limited

Rajendra Chopra
Company Secretary

Prepared by: Chirag Hotchandani